Innovage/$INNV
1D1W1MYTD1Y5YMAX
Capital at risk
About Innovage
InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. It manages its business as one reportable segment, PACE.
- Ticker
- $INNV
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,500
- Headquarters
- Denver, United States
- Website
- www.innovage.com
Innovage Metrics
BasicAdvanced
$1.5B
-
-$0.02
0.39
-
Price and volume
Market cap
$1.5B
Beta
0.39
52-week high
$12.64
52-week low
$3.94
Average daily volume
235K
Financial strength
Current ratio
1.051
Quick ratio
0.917
Long term debt to equity
0.274
Total debt to equity
0.324
Interest coverage (TTM)
0.94%
Profitability
EBITDA (TTM)
26.914
Gross margin (TTM)
68.47%
Net profit margin (TTM)
-0.26%
Operating margin (TTM)
0.58%
Effective tax rate (TTM)
356.77%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
0.67%
Return on equity (TTM)
-0.26%
Valuation
Price to revenue (TTM)
1.477
Price to book
6.22
Price to tangible book (TTM)
16.22
Price to free cash flow (TTM)
28.995
Free cash flow yield (TTM)
3.45%
Free cash flow per share (TTM)
0.371
Growth
Revenue change (TTM)
15.93%
Earnings per share change (TTM)
-91.07%
3-year revenue growth (CAGR)
12.88%
3-year earnings per share growth (CAGR)
-59.45%
What the Analysts think about Innovage
Analyst ratings (Buy, Hold, Sell) for Innovage stock.
Analyst projections of the future price of Innovage stock.
Bulls say / Bears say
FY2026 revenue increased 15.9% to $989.7 million, participant census grew to approximately 8,230, and management issued FY2027 revenue guidance of $1.05 billion to $1.085 billion. This supports a continued growth trajectory in the core capitated PACE business. (InnovAge)
Operating leverage improved materially: Center-level Contribution Margin rose 48.3% to $227.8 million, while Adjusted EBITDA increased to $94.6 million and its margin expanded to 9.6% from 4.0%. (InnovAge)
Liquidity strengthened during FY2026, with cash and cash equivalents rising to $97.9 million and short-term investments reaching $43.4 million, giving InnovAge greater capacity to fund operations, debt service, and center investments. (InnovAge)
FY2026 still ended with a $2.5 million net loss attributable to InnovAge despite sharply higher Adjusted EBITDA, while the company recorded $52.4 million of litigation costs and settlements. This highlights that reported earnings remain vulnerable to non-operating and compliance-related charges. (InnovAge)
Regulatory remediation continues to constrain expansion: California’s DHCS has an ongoing corrective-action process, suspended attestations for planned de novo centers, and precluded those centers from opening until deficiencies are addressed. (InnovAge Form 10-Q)
InnovAge remains exposed to legal and governance overhang from a proposed derivative-action settlement alleging failures involving PACE compliance, care-quality disclosures, and public filings; final court approval was scheduled for October 7, 2026. (InnovAge settlement notice)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
Innovage Financial Performance
Revenues and expenses
Innovage Earnings Performance
Company profitability
Upcoming events
No upcoming events
Innovage News
AllArticlesVideos
Funds containing Innovage
Fund name | Fund size | $INNV weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.